Pfizer Issues Multiple Note Series
Ticker: PFE · Form: 8-K · Filed: Nov 21, 2025 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.05, $500,000,000, $1,000,000,000, $1,250,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-issuance, financing, notes
Related Tickers: PFE
TL;DR
Pfizer just dropped new debt: notes due 2027, 2029, 2032, 2037, and 2045.
AI Summary
On November 18, 2025, Pfizer Inc. filed an 8-K report detailing the issuance of several series of notes. These include $1.000 Notes due 2027, $2.875 Notes due 2029, $3.250 Notes due 2032, $3.875 Notes due 2037, and $4.250 Notes due 2045. The filing indicates these notes were issued under the company's existing debt structure.
Why It Matters
This filing indicates Pfizer is actively managing its debt by issuing new notes, which could impact its capital structure and future financing costs.
Risk Assessment
Risk Level: low — The filing is a routine debt issuance announcement and does not contain any negative or unexpected information.
Key Numbers
- 2027 — Maturity Year (Maturity year for one series of notes)
- 2029 — Maturity Year (Maturity year for one series of notes)
- 2032 — Maturity Year (Maturity year for one series of notes)
- 2037 — Maturity Year (Maturity year for one series of notes)
- 2045 — Maturity Year (Maturity year for one series of notes)
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- November 18, 2025 (date) — Date of earliest event reported
- $1.000 Notes due 2027 (dollar_amount) — Debt instrument issued
- $2.875 Notes due 2029 (dollar_amount) — Debt instrument issued
- $3.250 Notes due 2032 (dollar_amount) — Debt instrument issued
- $3.875 Notes due 2037 (dollar_amount) — Debt instrument issued
- $4.250 Notes due 2045 (dollar_amount) — Debt instrument issued
FAQ
What is the aggregate principal amount of each series of notes issued by Pfizer?
The filing does not specify the aggregate principal amount for each series of notes, only the coupon rates and maturity dates.
What is the purpose of issuing these new notes?
The filing does not explicitly state the purpose, but it is a routine debt issuance, likely for general corporate purposes or refinancing.
Are these notes senior or subordinated debt?
The filing does not specify the seniority of these notes.
What are the specific interest rates for each note series?
The filing lists the interest rates as 1.000%, 2.875%, 3.250%, 3.875%, and 4.250% for the respective note series.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 18, 2025.
Filing Stats: 1,083 words · 4 min read · ~4 pages · Grade level 7.4 · Accepted 2025-11-21 16:16:49
Key Financial Figures
- $0.05 — ange on which registered Common Stock, $0.05 par value PFE New York Stock Exchan
- $500,000,000 — ompany") completed a public offering of $500,000,000 aggregate principal amount of Floating
- $1,000,000,000 — s due 2027 (the "Floating Rate Notes"), $1,000,000,000 aggregate principal amount of 3.875% No
- $1,250,000,000 — 200% Notes due 2030 (the "2030 Notes"), $1,250,000,000 aggregate principal amount of 4.500% No
Filing Documents
- d80089d8k.htm (8-K) — 43KB
- d80089dex11.htm (EX-1.1) — 168KB
- d80089dex12.htm (EX-1.2) — 61KB
- d80089dex42.htm (EX-4.2) — 366KB
- d80089dex51.htm (EX-5.1) — 21KB
- g80089g1121085102404.jpg (GRAPHIC) — 4KB
- g80089g59u60.jpg (GRAPHIC) — 6KB
- 0001193125-25-291406.txt ( ) — 924KB
- pfe-20251118.xsd (EX-101.SCH) — 5KB
- pfe-20251118_def.xml (EX-101.DEF) — 14KB
- pfe-20251118_lab.xml (EX-101.LAB) — 24KB
- pfe-20251118_pre.xml (EX-101.PRE) — 15KB
- d80089d8k_htm.xml (XML) — 10KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 1.1 Underwriting Agreement, dated November 18, 2025. 1.2 Pricing Agreement, dated November 18, 2025. 4.1 Indenture, dated as of September 7, 2018 (incorporated by reference from the Company's Current Report on Form 8-K filed on September 7, 2018). 4.2 Sixth Supplemental Indenture, dated as of November 21, 2025, between Pfizer Inc. and The Bank of New York Mellon, as trustee. 4.3 Form of Floating Rate Notes due 2027 (included in Exhibit 4.2). 4.4 Form of 3.875% Notes due 2027 (included in Exhibit 4.2). 4.5 Form of 4.200% Notes due 2030 (included in Exhibit 4.2). 4.6 Form of 4.500% Notes due 2032 (included in Exhibit 4.2). 4.7 Form of 4.875% Notes due 2035 (included in Exhibit 4.2). 4.8 Form of 5.600% Notes due 2055 (included in Exhibit 4.2). 4.9 Form of 5.700% Notes due 2065 (included in Exhibit 4.2). 5.1 Opinion of Margaret M. Madden, Senior Vice President and Corporate Secretary, Chief Governance Counsel of the Company. 23.1 Consent of Margaret M. Madden, Senior Vice President and Corporate Secretary, Chief Governance Counsel of the Company (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary, Chief Governance Counsel Dated: November 21, 2025